Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight
New York, USA, July 23, 2026 (GLOBE NEWSWIRE) -- Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight
The molecular glues competitive landscape report delivers important insights into approved as well as ongoing research of 90+ pipeline molecular glues, clinical strategies, upcoming therapeutics, and commercial analysis.
DelveInsight’s Molecular Glues Competitive Landscape 2026 report provides comprehensive global coverage of approved and pipeline molecular glues across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the molecular glues domain.
Key Takeaways from the Molecular Glues Pipeline Report
Request a sample and discover how do molecular glues enhance protein-protein interactions @ http://delveinsight.com/report-store/molecular-glues-competitive-landscape
What are Molecular Glues?
Molecular glues are a class of small molecules that induce or stabilize interactions between two proteins that would otherwise have little or no affinity for each other, thereby modulating cellular functions in a highly selective manner. Unlike traditional inhibitors that block the activity of a target protein, molecular glues promote the formation of a protein–protein complex, often leading to the degradation of disease-causing proteins through the ubiquitin-proteasome system. Many molecular glues function by recruiting a target protein to an E3 ubiquitin ligase, resulting in ubiquitination and subsequent proteasomal degradation of the target. This mechanism has emerged as a promising therapeutic strategy for addressing previously "undruggable" proteins, particularly in oncology, immunology, and neurodegenerative diseases. Notable examples include immunomodulatory drugs (IMiDs) such as thalidomide and its analogs, which act as molecular glues by redirecting the E3 ligase cereblon to degrade specific transcription factors. The growing interest in molecular glues stems from their ability to expand the druggable proteome and offer novel treatment approaches for diseases with limited therapeutic options.
To know more about the difference between PROTACs and molecular glues, visit @ Molecular Glues vs PROTACs Differences
Approved Molecular Glues Drug Profile Analysis
POMALYST: Bristol Myers Squibb
POMALYST® (pomalidomide) is a prescription medication indicated for adults with multiple myeloma in combination with dexamethasone. It is intended for patients who have previously undergone at least two prior therapies, including a proteasome inhibitor and lenalidomide, and whose disease has progressed during treatment or within 60 days after completing their most recent therapy. The safety and efficacy of POMALYST in pediatric patients have not been established.
REVLIMID: Bristol Myers Squibb
REVLIMID® (lenalidomide) is a prescription therapy used in adults with multiple myeloma, either in combination with dexamethasone or as maintenance treatment following autologous hematopoietic stem cell transplantation. It is not approved for the treatment of chronic lymphocytic leukemia (CLL) outside of controlled clinical studies, and its safety and effectiveness in children remain unknown. In addition to multiple myeloma, lenalidomide has received approvals across several hematologic malignancies, including follicular lymphoma, mantle cell lymphoma, marginal zone B-cell lymphoma, and myelodysplastic syndromes.
Find out more about are molecular glues easier to discover than PROTACs initial discovery feasibility @ Molecular Glues Analysis
A snapshot of the Pipeline Molecular Glues mentioned in the report:
Learn more about the emerging molecular glues @ Molecular Glues in Clinical Trials
As per Stuti Mahajan, consulting manager at DelveInsight, molecular glues represent a highly differentiated approach to targeted protein degradation, enabling the selective elimination of disease-causing proteins that are often considered “undruggable” by conventional modalities. As clinical validation grows, molecular glues are expected to attract significant investment and partnering activity, with the potential to expand treatment options across oncology, immunology, and neurodegenerative diseases while offering advantages in selectivity and drug-like properties.
Recent Developments in the Molecular Glues Treatment Space
Scope of the Molecular Glues Pipeline Report
Dive deep into rich insights for the history of molecular glues drug discovery, visit @ The Rise of Molecular Glues
Table of Contents
For further information on the recent developments in molecular glues, reach out @ Molecular Glues News
Related Reports
Molecular Glues Market
Molecular Glues Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key molecular glues companies, including Bristol Myers Squibb, Salarius Pharmaceuticals, Nested Therapeutics, Monte Rosa Therapeutics, and others.
PROTAC Market
PROTAC Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key PROTAC companies, including Pfizer, Arvinas, Celgene, Bristol Myers Squibb, Hinova Pharmaceuticals, and others.
Multiple Myeloma Market Report
Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies, including AstraZeneca (Gracell Biotechnologies), AbbVie, Active Biotech, Allogene Therapeutics, Amgen, Anaveon AG, Arcellx, Arcus Biosciences, Ascentage Pharma, BeiGene, Biohaven Pharmaceuticals, Biomea Fusion, Biotroy Therapeutics, bluebird bio, Bristol-Myers Squibb (Celgene), C4 Therapeutics, Caribou Biosciences, CARsgen Therapeutics, Cartesian Therapeutics, CASI Pharmaceuticals, CellCentric, Celularity, Celyad Oncology, Circio, Compugen, CRISPR Therapeutics, Fate Therapeutics, Fortvita Biologics, Gadeta, Galapagos, Genentech, Harpoon Therapeutics, Heidelberg Pharma, Ichnos Sciences, IDP Discovery Pharma S.L., IGM Biosciences, Immix Biopharma, Indapta Therapeutics, Ipsen, Janssen Research & Development, Johnson & Johnson, K36 Therapeutics, Luminary Therapeutics, ModernaTX, Mundipharma, Nanjing IASO Biotherapeutics, Nerviano Medical Sciences, Novartis, Oncotherapeutics, ORIC Pharmaceuticals, OriCell Therapeutics, Pfizer, Poseida Therapeutics, RAPA Therapeutics, Roche, Sanofi, Seagen, Sorrento Therapeutics, Sutro Biopharma, Takeda, and others.
Non-Small Cell Lung Cancer Market
Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies including BeiGene, Merus and Partner Therapeutics, Johnson & Johnson Innovative Medicine, Betta Pharma/Xcovery, CStone Pharmaceuticals, Bristol-Myers Squibb, Haihe Biopharma, Taiho Pharmaceutical, Takeda Pharmaceuticals, EMD Serono (Merck KGaA), Eli Lilly and Company, Merck, Regeneron/Sanofi, Ono Pharmaceutical, Novartis, Genentech/Roche, Amgen, Chugai Laboratories, Moderna Therapeutics, Pfizer, GSK, and others.
Non-Hodgkin’s Lymphoma Market
Non-Hodgkin’s Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key non-Hodgkin’s lymphoma companies, including Soligenix, Innate Pharma, Nurix Therapeutics, AstraZeneca, Merck, Prescient Therapeutics, Kite Pharma, Seagen, Takeda, Novartis, Daiichi Sankyo, Genmab, AbbVie, Genentech (a Member of Roche), Bristol Myers Squibb, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.